Update on Guidelines for the Management of Cancer‐Associated Thrombosis
Cancer‐associated thrombosis (CAT) is a major cause of morbidity and mortality in patients with cancer. Over the past 2 decades, enormous advances have been made in the management of CAT. The growing evidence base informing practice has led to the publication of a number of guidelines and guidance d...
Gespeichert in:
| Veröffentlicht in: | The oncologist (Dayton, Ohio) Jg. 26; H. 1; S. e24 - e40 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
Hoboken, USA
John Wiley & Sons, Inc
01.01.2021
Oxford University Press |
| Schlagworte: | |
| ISSN: | 1083-7159, 1549-490X, 1549-490X |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | Cancer‐associated thrombosis (CAT) is a major cause of morbidity and mortality in patients with cancer. Over the past 2 decades, enormous advances have been made in the management of CAT. The growing evidence base informing practice has led to the publication of a number of guidelines and guidance documents on the diagnosis and treatment of CAT. The goal of this review is to examine the latest versions of evidence‐based guidelines, highlighting the differences and similarities in their methodology, their disease‐specific content, and recommendations for management. Our analysis shows that for most clinical topics, the different guidelines provide roughly similar management advice. However, there are a number of important clinical topics in CAT that are not currently covered by the existing guidelines. We think inclusion of these topics in future versions of the guidelines will facilitate ongoing efforts to optimize the care of patients with CAT.
Implications for Practice
Cancer‐associated thrombosis (CAT) is a common complication in patients with cancer. This review examines the differences and similarities of the current CAT guidelines methods and recommendations. Current guidelines largely agree on many aspects of CAT management. However, there are a number of topics in CAT that are not currently included in guidelines where evidence‐based guidance would be very helpful for clinicians. Coverage of these topics in future guidelines is encouraged to optimize clinical practice.
Numerous guidelines for cancer‐associated thromboembolism have been published. This review compares recommendations from the most recent cancer‐specific guidelines, identifying areas in which guidance is lacking. |
|---|---|
| AbstractList | Cancer-associated thrombosis (CAT) is a major cause of morbidity and mortality in patients with cancer. Over the past 2 decades, enormous advances have been made in the management of CAT. The growing evidence base informing practice has led to the publication of a number of guidelines and guidance documents on the diagnosis and treatment of CAT. The goal of this review is to examine the latest versions of evidence-based guidelines, highlighting the differences and similarities in their methodology, their disease-specific content, and recommendations for management. Our analysis shows that for most clinical topics, the different guidelines provide roughly similar management advice. However, there are a number of important clinical topics in CAT that are not currently covered by the existing guidelines. We think inclusion of these topics in future versions of the guidelines will facilitate ongoing efforts to optimize the care of patients with CAT. Key Words. Cancer-associated thrombosis * Management * Prevention * Treatment * Guideline Cancer-associated thrombosis (CAT) is a major cause of morbidity and mortality in patients with cancer. Over the past 2 decades, enormous advances have been made in the management of CAT. The growing evidence base informing practice has led to the publication of a number of guidelines and guidance documents on the diagnosis and treatment of CAT. The goal of this review is to examine the latest versions of evidence-based guidelines, highlighting the differences and similarities in their methodology, their disease-specific content, and recommendations for management. Our analysis shows that for most clinical topics, the different guidelines provide roughly similar management advice. However, there are a number of important clinical topics in CAT that are not currently covered by the existing guidelines. We think inclusion of these topics in future versions of the guidelines will facilitate ongoing efforts to optimize the care of patients with CAT. Cancer‐associated thrombosis (CAT) is a major cause of morbidity and mortality in patients with cancer. Over the past 2 decades, enormous advances have been made in the management of CAT. The growing evidence base informing practice has led to the publication of a number of guidelines and guidance documents on the diagnosis and treatment of CAT. The goal of this review is to examine the latest versions of evidence‐based guidelines, highlighting the differences and similarities in their methodology, their disease‐specific content, and recommendations for management. Our analysis shows that for most clinical topics, the different guidelines provide roughly similar management advice. However, there are a number of important clinical topics in CAT that are not currently covered by the existing guidelines. We think inclusion of these topics in future versions of the guidelines will facilitate ongoing efforts to optimize the care of patients with CAT. Implications for Practice Cancer‐associated thrombosis (CAT) is a common complication in patients with cancer. This review examines the differences and similarities of the current CAT guidelines methods and recommendations. Current guidelines largely agree on many aspects of CAT management. However, there are a number of topics in CAT that are not currently included in guidelines where evidence‐based guidance would be very helpful for clinicians. Coverage of these topics in future guidelines is encouraged to optimize clinical practice. Numerous guidelines for cancer‐associated thromboembolism have been published. This review compares recommendations from the most recent cancer‐specific guidelines, identifying areas in which guidance is lacking. Cancer-associated thrombosis (CAT) is a major cause of morbidity and mortality in patients with cancer. Over the past 2 decades, enormous advances have been made in the management of CAT. The growing evidence base informing practice has led to the publication of a number of guidelines and guidance documents on the diagnosis and treatment of CAT. The goal of this review is to examine the latest versions of evidence-based guidelines, highlighting the differences and similarities in their methodology, their disease-specific content, and recommendations for management. Our analysis shows that for most clinical topics, the different guidelines provide roughly similar management advice. However, there are a number of important clinical topics in CAT that are not currently covered by the existing guidelines. We think inclusion of these topics in future versions of the guidelines will facilitate ongoing efforts to optimize the care of patients with CAT. IMPLICATIONS FOR PRACTICE: Cancer-associated thrombosis (CAT) is a common complication in patients with cancer. This review examines the differences and similarities of the current CAT guidelines methods and recommendations. Current guidelines largely agree on many aspects of CAT management. However, there are a number of topics in CAT that are not currently included in guidelines where evidence-based guidance would be very helpful for clinicians. Coverage of these topics in future guidelines is encouraged to optimize clinical practice.Cancer-associated thrombosis (CAT) is a major cause of morbidity and mortality in patients with cancer. Over the past 2 decades, enormous advances have been made in the management of CAT. The growing evidence base informing practice has led to the publication of a number of guidelines and guidance documents on the diagnosis and treatment of CAT. The goal of this review is to examine the latest versions of evidence-based guidelines, highlighting the differences and similarities in their methodology, their disease-specific content, and recommendations for management. Our analysis shows that for most clinical topics, the different guidelines provide roughly similar management advice. However, there are a number of important clinical topics in CAT that are not currently covered by the existing guidelines. We think inclusion of these topics in future versions of the guidelines will facilitate ongoing efforts to optimize the care of patients with CAT. IMPLICATIONS FOR PRACTICE: Cancer-associated thrombosis (CAT) is a common complication in patients with cancer. This review examines the differences and similarities of the current CAT guidelines methods and recommendations. Current guidelines largely agree on many aspects of CAT management. However, there are a number of topics in CAT that are not currently included in guidelines where evidence-based guidance would be very helpful for clinicians. Coverage of these topics in future guidelines is encouraged to optimize clinical practice. Numerous guidelines for cancer‐associated thromboembolism have been published. This review compares recommendations from the most recent cancer‐specific guidelines, identifying areas in which guidance is lacking. Cancer-associated thrombosis (CAT) is a major cause of morbidity and mortality in patients with cancer. Over the past 2 decades, enormous advances have been made in the management of CAT. The growing evidence base informing practice has led to the publication of a number of guidelines and guidance documents on the diagnosis and treatment of CAT. The goal of this review is to examine the latest versions of evidence-based guidelines, highlighting the differences and similarities in their methodology, their disease-specific content, and recommendations for management. Our analysis shows that for most clinical topics, the different guidelines provide roughly similar management advice. However, there are a number of important clinical topics in CAT that are not currently covered by the existing guidelines. We think inclusion of these topics in future versions of the guidelines will facilitate ongoing efforts to optimize the care of patients with CAT. IMPLICATIONS FOR PRACTICE: Cancer-associated thrombosis (CAT) is a common complication in patients with cancer. This review examines the differences and similarities of the current CAT guidelines methods and recommendations. Current guidelines largely agree on many aspects of CAT management. However, there are a number of topics in CAT that are not currently included in guidelines where evidence-based guidance would be very helpful for clinicians. Coverage of these topics in future guidelines is encouraged to optimize clinical practice. |
| Audience | Professional Academic |
| Author | Farge, Dominique Streiff, Michael B. Murphy, Martina Abutalib, Syed Ali Connors, Jean M. Piazza, Gregory |
| AuthorAffiliation | 5 Harvard Medical School Boston Massachusetts USA 3 Unité de Médecine Interne: Maladies Auto‐immunes et Pathologie Vasculaire (UF 04), Université de Paris, IRSL, Recherche clinique appliquée à l'hématologie Paris France 6 Cardiovascular Medicine Division at the Brigham and Women's Hospital Boston Massachusetts USA 8 Brigham and Womens Hospital and Dana‐Farber Cancer Institute Boston Massachusetts USA 2 Cancer Treatment Centers of America Chicago Illinois USA 4 Department of Medicine, McGill University Health Center Montreal Canada 7 Division of Hematology/Oncology, University of Florida Gainesville Florida USA 1 Division of Hematology, Department of Medicine, The Johns Hopkins University School of Medicine Baltimore Maryland USA |
| AuthorAffiliation_xml | – name: 8 Brigham and Womens Hospital and Dana‐Farber Cancer Institute Boston Massachusetts USA – name: 4 Department of Medicine, McGill University Health Center Montreal Canada – name: 5 Harvard Medical School Boston Massachusetts USA – name: 6 Cardiovascular Medicine Division at the Brigham and Women's Hospital Boston Massachusetts USA – name: 3 Unité de Médecine Interne: Maladies Auto‐immunes et Pathologie Vasculaire (UF 04), Université de Paris, IRSL, Recherche clinique appliquée à l'hématologie Paris France – name: 7 Division of Hematology/Oncology, University of Florida Gainesville Florida USA – name: 2 Cancer Treatment Centers of America Chicago Illinois USA – name: 1 Division of Hematology, Department of Medicine, The Johns Hopkins University School of Medicine Baltimore Maryland USA |
| Author_xml | – sequence: 1 givenname: Michael B. surname: Streiff fullname: Streiff, Michael B. email: mstreif@jhmi.edu organization: Division of Hematology, Department of Medicine, The Johns Hopkins University School of Medicine – sequence: 2 givenname: Syed Ali surname: Abutalib fullname: Abutalib, Syed Ali organization: Cancer Treatment Centers of America – sequence: 3 givenname: Dominique surname: Farge fullname: Farge, Dominique organization: Department of Medicine, McGill University Health Center – sequence: 4 givenname: Martina surname: Murphy fullname: Murphy, Martina organization: Division of Hematology/Oncology, University of Florida – sequence: 5 givenname: Jean M. surname: Connors fullname: Connors, Jean M. organization: Brigham and Womens Hospital and Dana‐Farber Cancer Institute – sequence: 6 givenname: Gregory surname: Piazza fullname: Piazza, Gregory organization: Division of Hematology/Oncology, University of Florida |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33275332$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kd1qFDEcxYNU7Ife-AAy4I0Is83nZHIjLIuthdq9acG7kMnHbmQmWZPZSu98hD6jT2K20xYrRQLJn-R3DiecQ7AXYrAAvEVwhiDExzHoOEOEieYFOECMipoK-G2vzLAlNUdM7IPDnL9DWEaCX4F9QjBnZTsAZ1cbo0ZbxVCdbr2xvQ82Vy6malzb6qsKamUHG8Yqumqhgrbp96_bec5R-yIz1eU6xaGL2efX4KVTfbZv7s8jcHXy-XLxpT5fnp4t5ue1Zow0teocVthwDi1krdIUc8x118COOUc6yJThQijc0IYR2IiWtpQ5IYxtDFKmI0fg0-S72XaDNbqES6qXm-QHlW5kVF4-fQl-LVfxWnIuKOKwGHy4N0jxx9bmUQ4-a9v3Kti4zRLThjcIC04L-n5CV6q30gcXi6Pe4XLOWygIKVkLNXuGKsvYwevSlfPl_ong3d9feMz-UEsBPk6ATjHnZN0jgqDcdS53ncu7zgsM_4G1H9Xo4-77vn9egibJz5Ls5j_mcnmxWE6aP8oAvtI |
| CitedBy_id | crossref_primary_10_1183_16000617_0004_2022 crossref_primary_10_7759_cureus_57860 crossref_primary_10_1016_j_ijcard_2022_09_049 crossref_primary_10_1001_jamanetworkopen_2023_25283 crossref_primary_10_1177_02184923241272913 crossref_primary_10_1038_s41598_024_75895_z crossref_primary_10_1182_bloodadvances_2021006484 crossref_primary_10_1111_bjh_18060 crossref_primary_10_1177_17562864221106362 crossref_primary_10_3390_cancers13081758 crossref_primary_10_1007_s00520_022_07297_8 crossref_primary_10_1007_s11239_024_02956_5 crossref_primary_10_1212_CON_0000000000001435 crossref_primary_10_3390_jcm11195970 crossref_primary_10_1007_s11912_023_01358_9 crossref_primary_10_1155_2022_2582923 crossref_primary_10_3389_fcvm_2022_917572 crossref_primary_10_3390_medicina60081369 crossref_primary_10_1186_s12885_023_10877_4 crossref_primary_10_3390_ijms23073573 crossref_primary_10_1055_a_2330_1371 crossref_primary_10_1007_s00520_022_07136_w crossref_primary_10_3389_fonc_2024_1282300 crossref_primary_10_1002_cpt_2649 crossref_primary_10_1016_j_rpth_2024_102359 crossref_primary_10_3389_fimmu_2022_1002652 crossref_primary_10_1007_s11864_023_01089_w crossref_primary_10_3390_cancers14092125 crossref_primary_10_1016_j_jaccao_2023_04_003 crossref_primary_10_51847_g8EP2icVsi crossref_primary_10_7759_cureus_64195 crossref_primary_10_1016_j_rpth_2023_100038 crossref_primary_10_1016_j_jchromb_2024_124425 crossref_primary_10_1002_cam4_70920 crossref_primary_10_1111_jth_15883 crossref_primary_10_3389_fcvm_2022_880698 crossref_primary_10_1155_2022_4488797 crossref_primary_10_3390_healthcare9060778 crossref_primary_10_1016_j_clinbiochem_2023_110613 crossref_primary_10_1016_j_jaccao_2024_01_006 crossref_primary_10_1016_j_jfma_2023_08_005 crossref_primary_10_1111_bjh_18995 crossref_primary_10_1016_j_ygyno_2024_02_011 crossref_primary_10_1111_jth_15739 crossref_primary_10_1161_CIR_0000000000001056 crossref_primary_10_1007_s11239_024_03009_7 crossref_primary_10_1016_j_jaccao_2023_10_009 crossref_primary_10_1186_s12959_021_00319_1 crossref_primary_10_1097_FJC_0000000000001142 crossref_primary_10_1016_j_ijsu_2021_106026 crossref_primary_10_1007_s11936_023_00998_1 crossref_primary_10_1016_j_thromres_2022_02_004 crossref_primary_10_3389_fcvm_2022_979631 crossref_primary_10_1080_03007995_2022_2128189 crossref_primary_10_1177_10760296241261364 crossref_primary_10_1177_17474930241239266 crossref_primary_10_38124_ijisrt_25jul1838 crossref_primary_10_1080_14740338_2025_2464113 crossref_primary_10_1007_s11060_022_03984_y crossref_primary_10_1002_ajh_27222 crossref_primary_10_1177_10781552221102311 crossref_primary_10_3390_cancers15184640 crossref_primary_10_2147_JBM_S411520 crossref_primary_10_1177_17562864231180717 crossref_primary_10_1007_s40140_024_00633_0 crossref_primary_10_1007_s10557_021_07211_0 crossref_primary_10_3389_fphar_2023_1263975 crossref_primary_10_3390_diseases9020034 crossref_primary_10_1016_j_jtha_2023_07_017 crossref_primary_10_1177_10760296221082988 crossref_primary_10_1080_1750743X_2025_2501922 crossref_primary_10_1007_s10585_021_10106_x crossref_primary_10_1007_s40261_022_01217_8 crossref_primary_10_1016_j_ijcard_2023_131271 crossref_primary_10_1016_j_thromres_2023_05_021 |
| Cites_doi | 10.1016/j.ejca.2011.09.015 10.6004/jnccn.2006.0071 10.1056/NEJMoa1814630 10.1016/S1470-2045(09)70232-3 10.1161/CIRCULATIONAHA.118.035418 10.1056/NEJMoa012385 10.1200/JCO.2018.78.8034 10.1093/annonc/mdj068 10.1056/NEJMoa1108898 10.1111/jth.14219 10.1200/JCO.2005.03.8877 10.1093/annonc/mdp052 10.1182/asheducation-2016.1.196 10.1056/NEJMoa1113572 10.1200/JCO.19.01461 10.1111/jth.12683 10.1016/S1470-2045(19)30336-5 10.1002/ajh.25603 10.1016/j.thromres.2019.08.021 10.1111/jth.14564 10.1056/NEJMoa1814468 10.1016/j.thromres.2010.10.001 10.1161/CIRCULATIONAHA.113.004450 10.1001/jamaoncol.2016.3350 10.1016/j.chest.2015.11.026 10.1007/s11239-016-1465-x 10.1056/NEJMoa0906598 10.1200/JCO.2007.14.1283 10.1056/NEJMoa1302507 10.1182/blood-2007-10-117051 10.1093/eurheartj/ehs408 10.1111/j.1538-7836.2006.02153.x 10.3324/haematol.2018.192419 10.1182/blood-2007-10-116327 10.1016/j.amjmed.2013.09.015 10.1002/bjs.1800840817 10.6004/jnccn.2018.7273 10.1111/jth.12338 10.1056/NEJMoa1007903 10.1111/jth.14015 10.1016/j.jacc.2017.06.047 10.1016/j.amjmed.2018.04.037 10.1111/jth.14662 10.1016/j.critrevonc.2006.05.001 10.1056/NEJMoa1915103 10.1007/s12094-019-02263-z 10.1056/NEJMoa1711948 10.1186/1477-9560-12-21 10.1016/j.ejca.2012.01.005 10.1056/NEJMoa1306638 |
| ContentType | Journal Article |
| Copyright | 2020 AlphaMed Press 2020 AlphaMed Press. COPYRIGHT 2021 Oxford University Press |
| Copyright_xml | – notice: 2020 AlphaMed Press – notice: 2020 AlphaMed Press. – notice: COPYRIGHT 2021 Oxford University Press |
| DBID | AAYXX CITATION NPM 7X8 5PM |
| DOI | 10.1002/onco.13596 |
| DatabaseName | CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic PubMed |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| DocumentTitleAlternate | Update on Guidelines for the Management of VTE |
| EISSN | 1549-490X |
| EndPage | e40 |
| ExternalDocumentID | PMC7794170 A780933799 33275332 10_1002_onco_13596 ONCO13596 |
| Genre | reviewArticle Research Support, Non-U.S. Gov't Journal Article Review |
| GeographicLocations | United States France |
| GeographicLocations_xml | – name: United States – name: France |
| GroupedDBID | --- 0R~ 123 18M 1OC 24P 2WC 36B 4.4 53G 5VS AAPXW AAVAP AAWTL AAZKR ABEJV ABPTD ABXVV ACXQS ADBBV ADXAS AEGXH AENEX AJAOE ALMA_UNASSIGNED_HOLDINGS AMNDL AOIJS BAWUL BFHJK CS3 DCZOG DIK DU5 E3Z EBD EBS EJD EMB EMOBN F5P FRP GROUPED_DOAJ GX1 H13 HYE HZ~ IAO IHR INH ITC LUTES LYRES O9- OK1 P2P P2W RAO RHF RHI ROL ROX RPM SUPJJ SV3 TOX TR2 UDS W2D W8F WIN WOHZO WOQ WOW XSB ZZTAW AAFWJ AAMMB AAYXX ABGNP AEFGJ AFPKN AGXDD AIDQK AIDYY ALUQN CITATION OVT NPM 7X8 5PM |
| ID | FETCH-LOGICAL-c5536-abf2a2d770e058ac42727cb60b5ff3b05ad799a26465306984845f99de6d1adb3 |
| IEDL.DBID | WIN |
| ISICitedReferencesCount | 89 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000595458200001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1083-7159 1549-490X |
| IngestDate | Tue Nov 04 01:44:25 EST 2025 Sun Nov 09 14:39:58 EST 2025 Sat Nov 29 14:15:23 EST 2025 Sat Nov 29 10:47:35 EST 2025 Wed Feb 19 02:29:03 EST 2025 Sat Nov 29 02:32:27 EST 2025 Tue Nov 18 21:36:28 EST 2025 Wed Jan 22 16:32:41 EST 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Prevention Guideline Treatment Management Cancer-associated thrombosis |
| Language | English |
| License | https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model 2020 AlphaMed Press. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c5536-abf2a2d770e058ac42727cb60b5ff3b05ad799a26465306984845f99de6d1adb3 |
| Notes | . Disclosures of potential conflicts of interest may be found at the end of this article ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 Disclosures of potential conflicts of interest may be found at the end of this article. No part of this article may be reproduced, stored, or transmitted in any form or for any means without the prior permission in writing from the copyright holder. For information on purchasing reprints contact commercialreprints@wiley.com. For permission information contact permissions@wiley.com. |
| OpenAccessLink | https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/onco.13596 |
| PMID | 33275332 |
| PQID | 2467612974 |
| PQPubID | 23479 |
| PageCount | 17 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_7794170 proquest_miscellaneous_2467612974 gale_infotracmisc_A780933799 gale_infotracacademiconefile_A780933799 pubmed_primary_33275332 crossref_primary_10_1002_onco_13596 crossref_citationtrail_10_1002_onco_13596 wiley_primary_10_1002_onco_13596_ONCO13596 |
| PublicationCentury | 2000 |
| PublicationDate | January 2021 |
| PublicationDateYYYYMMDD | 2021-01-01 |
| PublicationDate_xml | – month: 01 year: 2021 text: January 2021 |
| PublicationDecade | 2020 |
| PublicationPlace | Hoboken, USA |
| PublicationPlace_xml | – name: Hoboken, USA – name: United States |
| PublicationTitle | The oncologist (Dayton, Ohio) |
| PublicationTitleAlternate | Oncologist |
| PublicationYear | 2021 |
| Publisher | John Wiley & Sons, Inc Oxford University Press |
| Publisher_xml | – name: John Wiley & Sons, Inc – name: Oxford University Press |
| References | 1997; 84 2017; 3 2009; 20 2012; 366 2019; 94 2020; 382 2013; 369 2006; 17 2017; 43 2006; 59 2018; 103 2019; 17 2010; 363 2020; 38 2006; 4 2014; 371 2016; 149 2019; 380 2019; 182 2020; 18 2014; 129 2011; 127 2018; 131 2014; 127 2016; 1 2009; 10 2017; 70 2013; 11 2019; 20 2018; 138 2006; 24 2020 2013; 34 2018; 378 2002; 346 2020; 22 2009; 361 2012; 48 2008; 112 2008; 111 2014; 12 2018; 16 2007; 25 2018; 36 Raskob (2021122511450352100_onco13596-bib-0028) 2018; 378 Agnelli (2021122511450352100_onco13596-bib-0018) 2012; 366 Wang (2021122511450352100_onco13596-bib-0008) 2019; 17 McBane (2021122511450352100_onco13596-bib-0030) 2020; 18 Khorana (2021122511450352100_onco13596-bib-0050) 2006; 24 Lyman (2021122511450352100_onco13596-bib-0004) 2007; 25 Munoz Martin (2021122511450352100_onco13596-bib-0012) 2020; 22 Siegal (2021122511450352100_onco13596-bib-0037) 2013; 34 Young (2021122511450352100_onco13596-bib-0029) 2018; 36 Carrier (2021122511450352100_onco13596-bib-0020) 2019; 380 Rasmussen (2021122511450352100_onco13596-bib-0027) 2006; 4 Khorana (2021122511450352100_onco13596-bib-0019) 2008; 111 Wagman (2021122511450352100_onco13596-bib-0002) 2006; 4 Hokusai-VTE Investigators (2021122511450352100_onco13596-bib-0043) 2013; 369 Di Nisio (2021122511450352100_onco13596-bib-0048) 2011; 127 Schulman (2021122511450352100_onco13596-bib-0041) 2009; 361 Connors (2021122511450352100_onco13596-bib-0016) 2014; 371 EINSTEIN-PE Investigators (2021122511450352100_onco13596-bib-0040) 2012; 366 ENOXACAN Study Group (2021122511450352100_onco13596-bib-0025) 1997; 84 Agnelli (2021122511450352100_onco13596-bib-0031) 2020; 382 Kroger (2021122511450352100_onco13596-bib-0014) 2006; 17 Li (2021122511450352100_onco13596-bib-0023) 2019; 17 Spyropoulos (2021122511450352100_onco13596-bib-0035) 2019; 182 Siontis (2021122511450352100_onco13596-bib-0034) 2018; 138 Geldhof (2021122511450352100_onco13596-bib-0038) 2014; 12 Farge (2021122511450352100_onco13596-bib-0010) 2019; 20 Navi (2021122511450352100_onco13596-bib-0046) 2017; 70 Zoller (2021122511450352100_onco13596-bib-0052) 2012; 48 Grilz (2021122511450352100_onco13596-bib-0047) 2018; 103 EINSTEIN Investigators (2021122511450352100_onco13596-bib-0039) 2010; 363 Brenner (2021122511450352100_onco13596-bib-0049) 2018; 131 Streiff (2021122511450352100_onco13596-bib-0001) 2016; 1 Li (2021122511450352100_onco13596-bib-0022) 2017; 3 Kearon (2021122511450352100_onco13596-bib-0033) 2016; 149 Sanfilippo (2021122511450352100_onco13596-bib-0024) 2019; 94 Schulman (2021122511450352100_onco13596-bib-0042) 2014; 129 Mandala (2021122511450352100_onco13596-bib-0003) 2006; 59 Gerber (2021122511450352100_onco13596-bib-0015) 2008; 112 Agnelli (2021122511450352100_onco13596-bib-0017) 2009; 10 Khorana (2021122511450352100_onco13596-bib-0021) 2019; 380 Bergqvist (2021122511450352100_onco13596-bib-0026) 2002; 346 NCCN (2021122511450352100_onco13596-bib-0011) 2020 Carrier (2021122511450352100_onco13596-bib-0013) 2014; 127 Agnelli (2021122511450352100_onco13596-bib-0044) 2013; 369 Debourdeau (2021122511450352100_onco13596-bib-0005) 2009; 20 Khorana (2021122511450352100_onco13596-bib-0032) 2018; 16 Carrier (2021122511450352100_onco13596-bib-0009) 2013; 11 Key (2021122511450352100_onco13596-bib-0006) 2020; 38 Di Nisio (2021122511450352100_onco13596-bib-0007) 2014; 12 Hakeam (2021122511450352100_onco13596-bib-0036) 2017; 43 Zoller (2021122511450352100_onco13596-bib-0051) 2012; 48 Samuelson Bannow (2021122511450352100_onco13596-bib-0045) 2018; 16 |
| References_xml | – volume: 84 start-page: 1099 year: 1997 end-page: 1103 article-title: Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: A double‐blind randomized multicentre trial with venographic assessment publication-title: Br J Surg – volume: 10 start-page: 943 year: 2009 end-page: 949 article-title: Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: A randomised, placebo‐controlled, double‐blind study publication-title: Lancet Oncol – volume: 12 start-page: 21 year: 2014 article-title: Venous thromboembolism in the elderly: Efficacy and safety of non‐VKA oral anticoagulants publication-title: Thromb J – volume: 48 start-page: 121 year: 2012 end-page: 128 article-title: Risk of coronary heart disease in patients with cancer: A nationwide follow‐up study from Sweden publication-title: Eur J Cancer – volume: 371 start-page: 1263 year: 2014 end-page: 1264 article-title: Prophylaxis against venous thromboembolism in patients with cancer publication-title: N Engl J Med – volume: 34 start-page: 489 year: 2013 end-page: 498b article-title: Acute management of bleeding in patients on novel oral anticoagulants publication-title: Eur Heart J – volume: 127 start-page: 82 year: 2014 end-page: 86.e1 article-title: Lack of evidence to support thromboprophylaxis in hospitalized medical patients with cancer publication-title: Am J Med – volume: 16 start-page: 1891 year: 2018 end-page: 1894 article-title: Role of direct oral anticoagulants in the treatment of cancer‐associated venous thromboembolism: Guidance from the SSC of the ISTH publication-title: J Thromb Haemost – volume: 22 start-page: 171 year: 2020 end-page: 186 article-title: SEOM clinical guideline of venous thromboembolism (VTE) and cancer (2019) publication-title: Clin Transl Oncol – volume: 18 start-page: 411 year: 2020 end-page: 421 article-title: Apixaban and dalteparin in active malignancy‐associated venous thromboembolism: The ADAM VTE trial publication-title: J Thromb Haemost – volume: 1 start-page: 196 year: 2016 end-page: 205 article-title: Thrombosis in the setting of cancer publication-title: Hematology Am Soc Hematol Educ Program – volume: 361 start-page: 2342 year: 2009 end-page: 2352 article-title: RE‐COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism publication-title: N Engl J Med – volume: 366 start-page: 1287 year: 2012 end-page: 1297 article-title: Oral rivaroxaban for the treatment of symptomatic pulmonary embolism publication-title: N Engl J Med – volume: 346 start-page: 975 year: 2002 end-page: 980 article-title: Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer publication-title: N Engl J Med – volume: 3 start-page: 980 year: 2017 end-page: 988 article-title: Cardiovascular and thrombotic complications of novel multiple myeloma therapies: A review publication-title: JAMA Oncol – volume: 20 start-page: e566 year: 2019 end-page: e581 article-title: 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer publication-title: Lancet Oncol – volume: 112 start-page: 504 year: 2008 end-page: 510 article-title: The incidence of and risk factors for venous thromboembolism (VTE) and bleeding among 1,514 patients undergoing hematopoietic stem cell transplantation: Implications for VTE prevention publication-title: Blood – volume: 138 start-page: 1519 year: 2018 end-page: 1529 article-title: Outcomes associated with apixaban use in patients with end‐stage kidney disease and atrial fibrillation in the United States publication-title: Circulation – volume: 131 start-page: 1095 year: 2018 end-page: 1103 article-title: Arterial ischemic events are a major complication in cancer patients with venous thromboembolism publication-title: Am J Med – volume: 17 start-page: 1772 year: 2019 end-page: 1778 article-title: The use of direct oral anticoagulants for primary thromboprophylaxis in ambulatory cancer patients: Guidance from the SSC of the ISTH publication-title: J Thromb Haemost – volume: 182 start-page: 159 year: 2019 end-page: 166 article-title: Rivaroxaban versus warfarin treatment among morbidly obese patients with venous thromboembolism: Comparative effectiveness, safety, and costs publication-title: Thromb Res – volume: 111 start-page: 4902 year: 2008 end-page: 4907 article-title: Development and validation of a predictive model for chemotherapy‐associated thrombosis publication-title: Blood – volume: 129 start-page: 764 year: 2014 end-page: 772 article-title: RE‐COVER II Trial Investigators. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis publication-title: Circulation – volume: 149 start-page: 315 year: 2016 end-page: 352 article-title: Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report publication-title: Chest – volume: 363 start-page: 2499 year: 2010 end-page: 2510 article-title: Oral rivaroxaban for symptomatic venous thromboembolism publication-title: N Engl J Med – volume: 48 start-page: 1875 year: 2012 end-page: 1883 article-title: Risk of haemorrhagic and ischaemic stroke in patients with cancer: A nationwide follow‐up study from Sweden publication-title: Eur J Cancer – volume: 17 start-page: 840 year: 2019 end-page: 847 article-title: Derivation and validation of a risk assessment model for immunomodulatory drug‐associated thrombosis among patients with multiple myeloma publication-title: J Natl Compr Canc Netw – volume: 38 start-page: 496 year: 2020 end-page: 520 article-title: Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update publication-title: J Clin Oncol – volume: 20 start-page: 1459 year: 2009 end-page: 1471 article-title: 2008 SOR guidelines for the prevention and treatment of thrombosis associated with central venous catheters in patients with cancer: Report from the working group publication-title: Ann Oncol – volume: 11 start-page: 1760 year: 2013 end-page: 1765 article-title: Subcommittee on Haemostasis and Malignancy for the SSC of the ISTH. Management of challenging cases of patients with cancer‐associated thrombosis including recurrent thrombosis and bleeding: Guidance from the SSC of the ISTH publication-title: J Thromb Haemost – volume: 369 start-page: 799 year: 2013 end-page: 808 article-title: AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism publication-title: N Engl J Med – volume: 4 start-page: 838 year: 2006 end-page: 869 article-title: Venous thromboembolic disease. Clinical practice guidelines in oncology publication-title: J Natl Compr Canc Netw – volume: 127 start-page: 382 year: 2011 end-page: 383 article-title: Arterial thrombosis in ambulatory cancer patients treated with chemotherapy publication-title: Thromb Res – volume: 24 start-page: 484 year: 2006 end-page: 490 article-title: Thromboembolism in hospitalized neutropenic cancer patients publication-title: J Clin Oncol – volume: 369 start-page: 1406 year: 2013 end-page: 1415 article-title: Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism publication-title: N Engl J Med – volume: 12 start-page: 1746 year: 2014 end-page: 1749 article-title: Subcommittee on Haemostasis and Malignancy. Prevention of venous thromboembolism in hospitalized medical cancer patients: Guidance from the SSC of the ISTH publication-title: J Thromb Haemost – volume: 17 start-page: 297 year: 2006 end-page: 303 article-title: Risk factors for venous thromboembolic events in cancer patients publication-title: Ann Oncol – volume: 378 start-page: 615 year: 2018 end-page: 624 article-title: Edoxaban for the treatment of cancer‐associated venous thromboembolism publication-title: N Engl J Med – volume: 366 start-page: 601 year: 2012 end-page: 609 article-title: Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer publication-title: N Engl J Med – volume: 16 start-page: 1246 year: 2018 end-page: 1249 article-title: Management of cancer‐associated thrombosis in patients with thrombocytopenia: guidance from the SSC of the ISTH publication-title: J Thromb Haemost – volume: 380 start-page: 711 year: 2019 end-page: 719 article-title: Apixaban to prevent venous thromboembolism in patients with cancer publication-title: N Engl J Med – volume: 380 start-page: 720 year: 2019 end-page: 728 article-title: Rivaroxaban for thromboprophylaxis in high‐risk ambulatory patients with cancer publication-title: N Engl J Med – volume: 70 start-page: 926 year: 2017 end-page: 938 article-title: Risk of arterial thromboembolism in patients with cancer publication-title: J Am Coll Cardiol – volume: 36 start-page: 2017 year: 2018 end-page: 2023 article-title: Comparison of an oral factor Xa Inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: Results of a randomized trial (SELECT‐D) publication-title: J Clin Oncol – volume: 103 start-page: 1549 year: 2018 end-page: 1556 article-title: Frequency, risk factors, and impact on mortality of arterial thromboembolism in patients with cancer publication-title: Haematologica – year: 2020 – volume: 25 start-page: 5490 year: 2007 end-page: 5505 article-title: American society of clinical oncology guideline: Recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer publication-title: J Clin Oncol – volume: 4 start-page: 2384 year: 2006 end-page: 2390 article-title: Prolonged prophylaxis with dalteparin to prevent late thromboembolic complications in patients undergoing major abdominal surgery: A multicenter randomized open‐label study publication-title: J Thromb Haemost – volume: 59 start-page: 194 year: 2006 end-page: 204 article-title: Venous thromboembolism and cancer: Guidelines of the Italian Association of Medical Oncology (AIOM) publication-title: Crit Rev Oncol Hematol – volume: 94 start-page: 1176 year: 2019 end-page: 1184 article-title: Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score publication-title: Am J Hematol – volume: 43 start-page: 343 year: 2017 end-page: 351 article-title: Effect of major gastrointestinal tract surgery on the absorption and efficacy of direct acting oral anticoagulants (DOACs) publication-title: J Thromb Thrombolysis – volume: 382 start-page: 1599 year: 2020 end-page: 1607 article-title: Apixaban for the treatment of venous thromboembolism associated with cancer publication-title: N Engl J Med – volume: 48 start-page: 121 year: 2012 ident: 2021122511450352100_onco13596-bib-0052 article-title: Risk of coronary heart disease in patients with cancer: A nationwide follow-up study from Sweden publication-title: Eur J Cancer doi: 10.1016/j.ejca.2011.09.015 – volume: 4 start-page: 838 year: 2006 ident: 2021122511450352100_onco13596-bib-0002 article-title: Venous thromboembolic disease. Clinical practice guidelines in oncology publication-title: J Natl Compr Canc Netw doi: 10.6004/jnccn.2006.0071 – volume: 380 start-page: 720 year: 2019 ident: 2021122511450352100_onco13596-bib-0021 article-title: Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1814630 – volume: 10 start-page: 943 year: 2009 ident: 2021122511450352100_onco13596-bib-0017 article-title: Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: A randomised, placebo-controlled, double-blind study publication-title: Lancet Oncol doi: 10.1016/S1470-2045(09)70232-3 – volume: 138 start-page: 1519 year: 2018 ident: 2021122511450352100_onco13596-bib-0034 article-title: Outcomes associated with apixaban use in patients with end-stage kidney disease and atrial fibrillation in the United States publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.118.035418 – volume: 346 start-page: 975 year: 2002 ident: 2021122511450352100_onco13596-bib-0026 article-title: Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa012385 – volume: 36 start-page: 2017 year: 2018 ident: 2021122511450352100_onco13596-bib-0029 article-title: Comparison of an oral factor Xa Inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: Results of a randomized trial (SELECT-D) publication-title: J Clin Oncol doi: 10.1200/JCO.2018.78.8034 – volume: 17 start-page: 297 year: 2006 ident: 2021122511450352100_onco13596-bib-0014 article-title: Risk factors for venous thromboembolic events in cancer patients publication-title: Ann Oncol doi: 10.1093/annonc/mdj068 – volume: 366 start-page: 601 year: 2012 ident: 2021122511450352100_onco13596-bib-0018 article-title: Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1108898 – volume: 16 start-page: 1891 year: 2018 ident: 2021122511450352100_onco13596-bib-0032 article-title: Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: Guidance from the SSC of the ISTH publication-title: J Thromb Haemost doi: 10.1111/jth.14219 – volume: 24 start-page: 484 year: 2006 ident: 2021122511450352100_onco13596-bib-0050 article-title: Thromboembolism in hospitalized neutropenic cancer patients publication-title: J Clin Oncol doi: 10.1200/JCO.2005.03.8877 – volume: 20 start-page: 1459 year: 2009 ident: 2021122511450352100_onco13596-bib-0005 article-title: 2008 SOR guidelines for the prevention and treatment of thrombosis associated with central venous catheters in patients with cancer: Report from the working group publication-title: Ann Oncol doi: 10.1093/annonc/mdp052 – volume: 1 start-page: 196 year: 2016 ident: 2021122511450352100_onco13596-bib-0001 article-title: Thrombosis in the setting of cancer publication-title: Hematology Am Soc Hematol Educ Program doi: 10.1182/asheducation-2016.1.196 – volume: 366 start-page: 1287 year: 2012 ident: 2021122511450352100_onco13596-bib-0040 article-title: Oral rivaroxaban for the treatment of symptomatic pulmonary embolism publication-title: N Engl J Med doi: 10.1056/NEJMoa1113572 – volume: 38 start-page: 496 year: 2020 ident: 2021122511450352100_onco13596-bib-0006 article-title: Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update publication-title: J Clin Oncol doi: 10.1200/JCO.19.01461 – volume: 12 start-page: 1746 year: 2014 ident: 2021122511450352100_onco13596-bib-0007 article-title: Subcommittee on Haemostasis and Malignancy. Prevention of venous thromboembolism in hospitalized medical cancer patients: Guidance from the SSC of the ISTH publication-title: J Thromb Haemost doi: 10.1111/jth.12683 – volume: 20 start-page: e566 year: 2019 ident: 2021122511450352100_onco13596-bib-0010 article-title: 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer publication-title: Lancet Oncol doi: 10.1016/S1470-2045(19)30336-5 – volume: 371 start-page: 1263 year: 2014 ident: 2021122511450352100_onco13596-bib-0016 article-title: Prophylaxis against venous thromboembolism in patients with cancer publication-title: N Engl J Med – volume: 94 start-page: 1176 year: 2019 ident: 2021122511450352100_onco13596-bib-0024 article-title: Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score publication-title: Am J Hematol doi: 10.1002/ajh.25603 – volume: 182 start-page: 159 year: 2019 ident: 2021122511450352100_onco13596-bib-0035 article-title: Rivaroxaban versus warfarin treatment among morbidly obese patients with venous thromboembolism: Comparative effectiveness, safety, and costs publication-title: Thromb Res doi: 10.1016/j.thromres.2019.08.021 – volume: 17 start-page: 1772 year: 2019 ident: 2021122511450352100_onco13596-bib-0008 article-title: The use of direct oral anticoagulants for primary thromboprophylaxis in ambulatory cancer patients: Guidance from the SSC of the ISTH publication-title: J Thromb Haemost doi: 10.1111/jth.14564 – volume: 380 start-page: 711 year: 2019 ident: 2021122511450352100_onco13596-bib-0020 article-title: Apixaban to prevent venous thromboembolism in patients with cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1814468 – volume: 127 start-page: 382 year: 2011 ident: 2021122511450352100_onco13596-bib-0048 article-title: Arterial thrombosis in ambulatory cancer patients treated with chemotherapy publication-title: Thromb Res doi: 10.1016/j.thromres.2010.10.001 – volume: 129 start-page: 764 year: 2014 ident: 2021122511450352100_onco13596-bib-0042 article-title: RE-COVER II Trial Investigators. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.113.004450 – volume: 3 start-page: 980 year: 2017 ident: 2021122511450352100_onco13596-bib-0022 article-title: Cardiovascular and thrombotic complications of novel multiple myeloma therapies: A review publication-title: JAMA Oncol doi: 10.1001/jamaoncol.2016.3350 – volume: 149 start-page: 315 year: 2016 ident: 2021122511450352100_onco13596-bib-0033 article-title: Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report publication-title: Chest doi: 10.1016/j.chest.2015.11.026 – volume: 43 start-page: 343 year: 2017 ident: 2021122511450352100_onco13596-bib-0036 article-title: Effect of major gastrointestinal tract surgery on the absorption and efficacy of direct acting oral anticoagulants (DOACs) publication-title: J Thromb Thrombolysis doi: 10.1007/s11239-016-1465-x – volume: 361 start-page: 2342 year: 2009 ident: 2021122511450352100_onco13596-bib-0041 article-title: RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism publication-title: N Engl J Med doi: 10.1056/NEJMoa0906598 – volume: 25 start-page: 5490 year: 2007 ident: 2021122511450352100_onco13596-bib-0004 article-title: American society of clinical oncology guideline: Recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer publication-title: J Clin Oncol doi: 10.1200/JCO.2007.14.1283 – volume: 369 start-page: 799 year: 2013 ident: 2021122511450352100_onco13596-bib-0044 article-title: AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism publication-title: N Engl J Med doi: 10.1056/NEJMoa1302507 – volume: 112 start-page: 504 year: 2008 ident: 2021122511450352100_onco13596-bib-0015 article-title: The incidence of and risk factors for venous thromboembolism (VTE) and bleeding among 1,514 patients undergoing hematopoietic stem cell transplantation: Implications for VTE prevention publication-title: Blood doi: 10.1182/blood-2007-10-117051 – year: 2020 ident: 2021122511450352100_onco13596-bib-0011 – volume: 34 start-page: 489 year: 2013 ident: 2021122511450352100_onco13596-bib-0037 article-title: Acute management of bleeding in patients on novel oral anticoagulants publication-title: Eur Heart J doi: 10.1093/eurheartj/ehs408 – volume: 4 start-page: 2384 year: 2006 ident: 2021122511450352100_onco13596-bib-0027 article-title: Prolonged prophylaxis with dalteparin to prevent late thromboembolic complications in patients undergoing major abdominal surgery: A multicenter randomized open-label study publication-title: J Thromb Haemost doi: 10.1111/j.1538-7836.2006.02153.x – volume: 103 start-page: 1549 year: 2018 ident: 2021122511450352100_onco13596-bib-0047 article-title: Frequency, risk factors, and impact on mortality of arterial thromboembolism in patients with cancer publication-title: Haematologica doi: 10.3324/haematol.2018.192419 – volume: 111 start-page: 4902 year: 2008 ident: 2021122511450352100_onco13596-bib-0019 article-title: Development and validation of a predictive model for chemotherapy-associated thrombosis publication-title: Blood doi: 10.1182/blood-2007-10-116327 – volume: 127 start-page: 82 year: 2014 ident: 2021122511450352100_onco13596-bib-0013 article-title: Lack of evidence to support thromboprophylaxis in hospitalized medical patients with cancer publication-title: Am J Med doi: 10.1016/j.amjmed.2013.09.015 – volume: 84 start-page: 1099 year: 1997 ident: 2021122511450352100_onco13596-bib-0025 article-title: Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: A double-blind randomized multicentre trial with venographic assessment publication-title: Br J Surg doi: 10.1002/bjs.1800840817 – volume: 17 start-page: 840 year: 2019 ident: 2021122511450352100_onco13596-bib-0023 article-title: Derivation and validation of a risk assessment model for immunomodulatory drug-associated thrombosis among patients with multiple myeloma publication-title: J Natl Compr Canc Netw doi: 10.6004/jnccn.2018.7273 – volume: 11 start-page: 1760 year: 2013 ident: 2021122511450352100_onco13596-bib-0009 article-title: Subcommittee on Haemostasis and Malignancy for the SSC of the ISTH. Management of challenging cases of patients with cancer-associated thrombosis including recurrent thrombosis and bleeding: Guidance from the SSC of the ISTH publication-title: J Thromb Haemost doi: 10.1111/jth.12338 – volume: 363 start-page: 2499 year: 2010 ident: 2021122511450352100_onco13596-bib-0039 article-title: Oral rivaroxaban for symptomatic venous thromboembolism publication-title: N Engl J Med doi: 10.1056/NEJMoa1007903 – volume: 16 start-page: 1246 year: 2018 ident: 2021122511450352100_onco13596-bib-0045 article-title: Management of cancer-associated thrombosis in patients with thrombocytopenia: guidance from the SSC of the ISTH publication-title: J Thromb Haemost doi: 10.1111/jth.14015 – volume: 70 start-page: 926 year: 2017 ident: 2021122511450352100_onco13596-bib-0046 article-title: Risk of arterial thromboembolism in patients with cancer publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2017.06.047 – volume: 131 start-page: 1095 year: 2018 ident: 2021122511450352100_onco13596-bib-0049 article-title: RIETE Investigators. Arterial ischemic events are a major complication in cancer patients with venous thromboembolism publication-title: Am J Med doi: 10.1016/j.amjmed.2018.04.037 – volume: 18 start-page: 411 year: 2020 ident: 2021122511450352100_onco13596-bib-0030 article-title: Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial publication-title: J Thromb Haemost doi: 10.1111/jth.14662 – volume: 59 start-page: 194 year: 2006 ident: 2021122511450352100_onco13596-bib-0003 article-title: Venous thromboembolism and cancer: Guidelines of the Italian Association of Medical Oncology (AIOM) publication-title: Crit Rev Oncol Hematol doi: 10.1016/j.critrevonc.2006.05.001 – volume: 382 start-page: 1599 year: 2020 ident: 2021122511450352100_onco13596-bib-0031 article-title: Apixaban for the treatment of venous thromboembolism associated with cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1915103 – volume: 22 start-page: 171 year: 2020 ident: 2021122511450352100_onco13596-bib-0012 article-title: SEOM clinical guideline of venous thromboembolism (VTE) and cancer (2019) publication-title: Clin Transl Oncol doi: 10.1007/s12094-019-02263-z – volume: 378 start-page: 615 year: 2018 ident: 2021122511450352100_onco13596-bib-0028 article-title: Edoxaban for the treatment of cancer-associated venous thromboembolism publication-title: N Engl J Med doi: 10.1056/NEJMoa1711948 – volume: 12 start-page: 21 year: 2014 ident: 2021122511450352100_onco13596-bib-0038 article-title: Venous thromboembolism in the elderly: Efficacy and safety of non-VKA oral anticoagulants publication-title: Thromb J doi: 10.1186/1477-9560-12-21 – volume: 48 start-page: 1875 year: 2012 ident: 2021122511450352100_onco13596-bib-0051 article-title: Risk of haemorrhagic and ischaemic stroke in patients with cancer: A nationwide follow-up study from Sweden publication-title: Eur J Cancer doi: 10.1016/j.ejca.2012.01.005 – volume: 369 start-page: 1406 year: 2013 ident: 2021122511450352100_onco13596-bib-0043 article-title: Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism publication-title: N Engl J Med doi: 10.1056/NEJMoa1306638 |
| SSID | ssj0015932 |
| Score | 2.590087 |
| SecondaryResourceType | review_article |
| Snippet | Cancer‐associated thrombosis (CAT) is a major cause of morbidity and mortality in patients with cancer. Over the past 2 decades, enormous advances have been... Cancer-associated thrombosis (CAT) is a major cause of morbidity and mortality in patients with cancer. Over the past 2 decades, enormous advances have been... Numerous guidelines for cancer‐associated thromboembolism have been published. This review compares recommendations from the most recent cancer‐specific... |
| SourceID | pubmedcentral proquest gale pubmed crossref wiley |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | e24 |
| SubjectTerms | Analysis Anticoagulants (Medicine) Blood clot Cancer Cancer‐associated thrombosis Care and treatment Complications and side effects Evaluation Evidence-based medicine France Guideline Health aspects Management Management science Mortality Practice guidelines (Medicine) Prevention Risk factors Special Series: Approach to the Patient with Cancer and Thrombosis Thrombosis Treatment Web applications |
| Title | Update on Guidelines for the Management of Cancer‐Associated Thrombosis |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fonco.13596 https://www.ncbi.nlm.nih.gov/pubmed/33275332 https://www.proquest.com/docview/2467612974 https://pubmed.ncbi.nlm.nih.gov/PMC7794170 |
| Volume | 26 |
| WOSCitedRecordID | wos000595458200001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVASL databaseName: Oxford Journals Open Access Collection customDbUrl: eissn: 1549-490X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0015932 issn: 1083-7159 databaseCode: TOX dateStart: 19960101 isFulltext: true titleUrlDefault: https://academic.oup.com/journals/ providerName: Oxford University Press – providerCode: PRVWIB databaseName: Wiley Online Library Free Content customDbUrl: eissn: 1549-490X dateEnd: 20211231 omitProxy: false ssIdentifier: ssj0015932 issn: 1083-7159 databaseCode: WIN dateStart: 19960101 isFulltext: true titleUrlDefault: https://onlinelibrary.wiley.com providerName: Wiley-Blackwell |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3ditQwFD6si4g3_rtW1yWiIApl26RpGvBmGVxd0BkvZnXuQpKm7IC2y3THax_BZ_RJzEk7ne0ignhTWnJakvT85px8AXhBqyyvjBGx1ozGmcx1rJ3lsUs1tagAeah2__xBTKfFYiE_7cCbzV6YDh9iWHBDyQj6GgVcm_ZwCxra1LbBUxsk4m2nWYrHF3w5mQ4pBC5Zl-osWCz804BNSg-3r46s0VWdfMkoXS2YvOzIBkt0fPv_xnAHbvUeKDnqWOYu7Lj6Htz42OfY78PJ6TmuApCmJu_WCIKFhfHE-7bE-4pkWy5DmopMkGdWv3783PxlV5L52ar5Zpp22T6A0-O388n7uD9wIbacszzWpqKalkIkLuGFthn13o01eWJ4VTGTcF0KKbX3oXLuQw1ZZEXGKylLl5epLg17CLt1U7tHQGTqGGeUZRiDmRLTrQmjumBaY2bWRvBqM_HK9mjkeCjGV9XhKFOFc6PC3ETwfKA97zA4_kj1Ev-fQsH0X7K631_g-4MQV-pIFLh64wcQwf6I0guUHTU_23CAwiasQqtds24V9VbFe4Q-BItgr-OIoUOMUR_5MRqBGPHKQIA43uOWenkW8LyF14mpSCJ4HXjlL2NUs-lkFu4e_wvxE7hJsRQnrBztw-7Fau2ewnX7_WLZrg7gmlgU_jqfLQ6CCP0Gq5Uc_g |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB5BQcCF9yNQwAgkVKSoWTuO42O1onTFNuWwhd4s23HUlSCpdruc-Qn8Rn4JHiebbSqEhLgl8iTyY16eGX8GeEOrNKuMEbHWjMapzHSsneWxG2lqUQHyUO3-eSqKIj85kZ-62hw8C9PiQ_QBN5SMoK9RwDEgvbtBDW1q2-C1DTK7CtdS72ngzQ1fJkWfROCStcnOnMXCv_XopHR38-3AHl3WyhfM0uWSyYuubLBF-3f-cxR34XbnhJK9lmvuwRVX34cbh12a_QFMjs8wEECamnxYIQ4W1sYT794S7y6STcUMaSoyRrZZ_Prxc73QriSz00XzzTTL-fIhHO-_n40P4u7OhdhyzrJYm4pqWgqRuITn2qbUOzjWZInhVcVMwnUppNTejcq4323IPM1TXklZuqwc6dKwR7BVN7V7AkSOHOOMshS3YabEjGvCqM6Z1pictRHsrGde2Q6QHO_F-KpaKGWqcG5UmJsIXve0Zy0Mxx-p3uICKpRN_yeruyMGvj-IcqX2RI4BHD-ACLYHlF6m7KD51ZoFFDZhIVrtmtVSUW9YvFPod2ERPG5Zou8QY9Rv_hiNQAyYpSdAKO9hSz0_DZDewqvFkUgieBeY5S9jVEfF-Cg8Pf0X4pdw82B2OFXTSfHxGdyiWJkTAknbsHW-WLnncN1-P58vFy-CDP0G-W0fGA |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB5BQRUX3o9AASOQEEhRs3Ycx8dqYWFFSXtoUW-W7TjqSm2y2u1y5ifwG_kleJxstqkQEuKWyJPIj5nxvPwZ4A2t0qwyRsRaMxqnMtOxdpbHbqSpRQXIQ7X7t31RFPnJiTzsanPwLEyLD9EH3FAygr5GAXfzstrdoIY2tW3w2gaZXYcbaeYdcjxQMi36JAKXrE125iwW_q1HJ6W7m28H-9FVrXxpW7paMnnZlA170eTOf47iLtzujFCy13LNPbjm6vuw_bVLsz-A6fEcAwGkqcmnFeJgYW088eYt8eYi2VTMkKYiY2Sbxa8fP9cL7UpydLpozk2znC0fwvHk49H4c9zduRBbzlkWa1NRTUshEpfwXNuUegPHmiwxvKqYSbguhZTam1EZ996GzNM85ZWUpcvKkS4NewRbdVO7J0DkyDHOKEvRDTMlZlwTRnXOtMbkrI3g3Xrmle0AyfFejDPVQilThXOjwtxE8LqnnbcwHH-keosLqFA2_Z-s7o4Y-P4gypXaEzkGcPwAItgZUHqZsoPmV2sWUNiEhWi1a1ZLRf3G4o1C74VF8Lhlib5DjFHv_DEagRgwS0-AUN7Dlnp2GiC9hVeLI5FE8D4wy1_GqA6K8UF4evovxC9h-_DDRO1Piy_P4BbFwpwQR9qBrYvFyj2Hm_b7xWy5eBFE6Dd2pR6c |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Update+on+Guidelines+for+the+Management+of+Cancer-Associated+Thrombosis&rft.jtitle=The+oncologist+%28Dayton%2C+Ohio%29&rft.au=Streiff%2C+Michael+B&rft.au=Abutalib%2C+Syed+Ali&rft.au=Farge%2C+Dominique&rft.au=Murphy%2C+Martina&rft.date=2021-01-01&rft.pub=Oxford+University+Press&rft.issn=1083-7159&rft.volume=26&rft.issue=1&rft.spage=e24&rft_id=info:doi/10.1002%2Fonco.13596&rft.externalDocID=A780933799 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1083-7159&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1083-7159&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1083-7159&client=summon |